Published in final edited form as:

Expert Opin Drug Deliv. 2011 September ; 8(9): 1161–1174. doi:10.1517/17425247.2011.588207.

Intracochlear Drug Delivery Systems

Jeffrey T. Borenstein

Biomedical Engineering Center, Draper Laboratory, Cambridge MA 02139

Abstract

Introduction—Advances in molecular biology and in the basic understanding of the mechanisms associated with sensorineural hearing loss and other diseases of the inner ear, are paving the way towards new approaches for treatments for millions of patients. However, the cochlea is a particularly challenging target for drug therapy, and new technologies will be required to provide safe and efficacious delivery of these compounds. Emerging delivery systems based on microfluidic technologies are showing promise as a means for direct intracochlear delivery. Ultimately, these systems may serve as a means for extended delivery of regenerative compounds to restore hearing in patients suffering from a host of auditory diseases.

Areas covered in this review—Recent progress in the development of drug delivery systems capable of direct intracochlear delivery is reviewed, including passive systems such as osmotic pumps, active microfluidic devices, and systems combined with currently available devices such as cochlear implants. The aim of this article is to provide a concise review of intracochlear drug delivery systems currently under development, and ultimately capable of being combined with emerging therapeutic compounds for the treatment of inner ear diseases.

Expert Opinion—Safe and efficacious treatment of auditory diseases will require the development of microscale delivery devices, capable of extended operation and direct application to the inner ear. These advances will require miniaturization and integration of multiple functions, including drug storage, delivery, power management and sensing, ultimately enabling closed-loop control and timed-sequence delivery devices for treatment of these diseases.

Keywords

Intracochlear; Drug Delivery; Regeneration; Hair Cells; Microfluidics; Computational Models; Microelectronics

1. Introduction

Disorders of the inner ear comprise the largest and most serious class of diseases responsible for hearing loss, with 250 million people worldwide suffering from disabling hearing loss [1]. In the United States alone, 28 million patients suffer from sensorineural hearing loss (SNHL), a condition that currently causes an irreversible decline in cochlear function, and profound deafness remains the most prevalent serious medical condition at birth, with 3 in 1000 newborns suffering from this condition. In addition to these auditory disorders, a host of vestibular conditions such as Meniere's disease affect millions of patients, and tinnitus remains an intractable problem for many patients and the most common and expensive condition for the US Department of Defense treating Armed Forces personnel who have

Contact Information: Jeffrey T. Borenstein, Draper Laboratory, Mail Stop 32, 555 Technology Square, Cambridge, MA 02139, Tel: (617) 258-1686, Fax: (617) 258-4238, jborenstein@draper.com.

7 Declaration of Interest

The author states no conflicts of interest and did not receive any payments towards completion of this manuscript.

suffered a blast-related injury [2] with tympanic membrane perforation a common marker of blast injury [3]. A partial list of inner ear diseases potentially amenable to intracochlear drug delivery is provided in Table I.

Spurred by the rising incidence of inner ear diseases, researchers have made significant advances in understanding the basic mechanisms and molecular biology of diseases of the inner ear and have identified potential pathways for regeneration and restoration of hair cell and neural cell function in the inner ear [1]. These approaches encompass the use of stem cells, gene therapy, as well as neurotrophin- and RNA interference-based systems. While significant hurdles remain before these therapies become available for human clinical use, they hold promise as avenues for restoration of hearing and other inner ear functions for patients with no currently available relief for these devastating diseases [4]. The principal challenge in treatment of inner ear diseases remains the inaccessibility of targets for therapy, due largely to the presence of the blood-cochlear barrier. Oral medications are typically blocked by the blood-cochlear barrier, and therefore clinicians have resorted to delivering drugs intratympanically for a range of conditions auditory and vestibular conditions [5]. Intratympanic delivery of compounds for treatment of inner ear diseases relies upon diffusion through the round window membrane (RWM), a structure with widely disparate transport properties depending upon the patient and disease state. This variability results in poor dosage control, and coupled with the reliance on passive diffusion mechanisms to transport drugs along the length of the cochlea, has limited the effectiveness of intratympanic delivery. Recent efforts have therefore shifted toward intracochlear drug delivery approaches, the subject of this review, as a means to directly and controllably deliver medications to specific targets in the inner ear [6].

Intracochlear delivery systems typically comprise micropumps with active or passive control systems, either as a standalone device or in combination with a cochlear implant. Initial efforts have focused on the use of osmotic pumps [7,8], passive devices that are sufficiently small to enable implantation but have limited lifetime and lack control over delivery parameters [9,10]. More recently, microfluidic systems have emerged, providing either constant drug infusion [11,12,13,14] or reciprocating delivery using a micropump [15,16,17,18]. These approaches offer the opportunity to provide precise control over delivery, for extended periods of treatment, and with the potential for combination therapies in a timed-sequence fashion. In addition to demonstrating efficacy, these systems must be proven safe, with a low risk of infection, repeated surgical procedures or damage to hearing structures with associated further hearing loss. Further, they may be combined with sensors for real-time measurement of drug concentration, flow rate and bioactivity. One avenue for clinical introduction of these delivery systems is the integration of a delivery device with a cochlear implant, thus providing regenerative therapy as well as restoring hearing [19,20,21]. These emerging technologies and the intracochlear systems they will enable have the potential to revolutionize treatment of diseases of the inner ear.

2. Inner Ear Diseases and Therapeutic Approaches

a. Cochlear Physiology and Function: Considerations for Drug Delivery Systems

The cochlea, the organ of hearing, resides along with the vestibular organ in the inner ear, and is responsible for converting mechanical signals from the middle ear into electrical signals that are transmitted along the auditory nerve toward the brainstem. It is the small size and remote location of the cochlea that render direct drug delivery to the organ so difficult. The cochlea, roughly 32 mm in length in humans, comprises three coiled fluid-filled tubes, the scala tympani (ST), scala vestibuli, and scala media [22]. The ST terminates at the round window membrane (RWM), a structure that may be used for direct intracochlear delivery as will be described later. The scala vestibuli terminates at the oval window, which houses the

stapes or footplate that transmits mechanical signals from the middle ear. The scala vestibuli and tympani connect to each other at the apex of the cochlea via the helicotrema. Sound from the outer ear causes motion of the eardrum or tympanic membrane, which in turn generates motion of the fluids in the inner ear. The cochlea contains the Organ of Corti (OC), which comprises three rows of outer hair cells (OHC) and one row of inner hair cells (IHC) along a basilar membrane. The IHCs respond to the waveform of a sound stimulus by releasing neurotransmitters to activate auditory nerve fibers. Loss of function of the hair cells and auditory neurons result in hearing loss, and one of the prevailing goals of intracochlear drug delivery systems is to provide therapeutic agents directly to the cochlea to effect regeneration of these sensorineural cells [23].

The two principal fluids present in the cochlea are perilymph and endolymph. Perilymph bears some similarities to cerebrospinal fluid (CSF), but its protein concentration is roughly an order of magnitude higher than CSF and its composition is a little different [24,25]. Perilymph is in direct contact with the basolateral surface of the hair cells and auditory neurons; its composition is of importance in understanding drug delivery kinetics in the cochlea [26]. Endolymph, the fluid contained within the scala media, bathes the apical surface of hair cells and has an ionic composition similar to the intracellular fluid environment. The cochlea contains a highly vascularized region known as the stria vascularis that maintains a unique electrochemical environment that supports transduction of sound by the IHC.

Surgical access to the inner ear is perhaps the most critical aspect of direct intracochlear drug delivery. As mentioned earlier, one potential route of administration is directly through the RWM, thereby eliminating the challenge intratympanic delivery methods encounter related to compound diffusion across the membrane. Another potential access point for intracochlear drug delivery is through a cochleostomy, a hole drilled surgically through the cochlear bone [27]. A cochleostomy into the ST has been established as the preferred entry technique for insertion of multielectrode cochlear implants [28]. Minimization of surgical trauma associated with this technique is important for preservation of residual hearing structures in cochlear implant recipients. For drug delivery applications, preservation of hearing structures and minimization of surgical trauma are paramount. Other important aspects of the surgical procedure and placement of drug delivery devices that are beyond the scope of this review are the establishment of a robust, leak-proof seal at the site of insertion of the delivery system and avoidance of foreign body rejection, inflammatory response and biofouling of the device by the patient's immune system.

Functional assessment of hearing utilizes a well-established set of electrophysiological parameters with known effects on specific hearing structures. These include Distortion Product OtoAcoustic Emissions (DPOAE) and the Auditory Brainstem Response (ABR) [29], both of which are all useful clinically but will be discussed here in the context of intracochlear drug delivery experiments. In addition, Compound Action Potential (CAP) measurements are often used in drug delivery experiments to evaluate delivery kinetics. Each of these can be assessed at specific frequencies; the tonotopic arrangement of the cochlea provides a spatial map of hair cell function due to the correlation between particular frequency response and position along the length of the cochlea, as shown in Figure 1. Measurement of DPOAE is accomplished by introducing two tone pips with predetermined sound levels and frequencies into the ear canal; the inner ear generates acoustic emissions as a result of mechanical motion of the basilar membrane that provide a direct assessment of the function of the OHC. One particularly useful application of DPOAE measurements in drug delivery experiments is as a baseline measurement to assess surgically-induced trauma [30,31]. The CAP measurement is a far-field electrocochleographic technique that monitors nerve fiber response to tone pips, often by using a ball electrode positioned in the vicinity of

the RWM [32]. This technique can be used as a measure of cochlear function at specific frequencies, providing a map of hair cell function through the cochlea during drug delivery experiments.

Assessment of pharmacokinetics and pharmacodynamics are critical aspects of the development of drug delivery systems [33]. For intracochlear delivery, these present particular challenges because of the remoteness and small size of hearing structures, and difficulties in imaging drug transport. Ultimately, development of drug delivery systems for specific clinical applications will require functional assessment of the mechanism and disease the drug-device combination is targeting. However, early stage drug delivery technology development can benefit significantly from the use of surrogate compounds with known, predictable and reversible effects on hearing [34]. Use of these surrogates has been invoked in the development of kinetic models describing drug delivery as a function of delivery parameters and the structural and biochemical environment of the cochlea [15].

b. Auditory Diseases

Among auditory diseases, the most prevalent condition is Sensorineural Hearing Loss (SNHL), afflicting some 28 million individuals in the United States and hundreds of millions worldwide [1]. Aging of the population is expected to double these numbers within the next two decades. Principal causes of SNHL include damage to, or death of hair cells as a result of noise, drug ototoxicity and aging, resulting in communication difficulties and social withdrawal and ultimately profound deafness. Current treatments are based upon hearing assist devices including hearing aids and cochlear implants, neither of which arrests progressive hearing loss nor restores hair cell function. Therapeutic approaches for SNHL are emerging, as shown in Table II, including pharmacologic compounds, growth factors, and stem cells.

A number of more immediate auditory applications of intracochlear drug delivery are being pursued, many with significant patient populations and all in need of significant advances towards improved outcomes. Principal among these is Noise-Induced Hearing Loss (NIHL), brought about by either acute or chronic noise exposure [35]. Steroids, growth factors and antioxidants are being explored [36], but lack methods for direct intracochlear delivery and therefore provide limited benefit while in some cases causing significant side effects. Of particular urgency is the incidence of NIHL in members of the Armed Services exposed chronically to engine noise or acutely in the battlefield. Incidence of NIHL has also been a concern in younger patients due to exposure to personal music players.

Ototoxicity due to chemotherapy [37] and radiation therapy in cancer patients represents an urgent condition requiring advances in drug delivery technology [38]. Cisplatin, a commonly used chemotherapeutic agent, is known to cause significant and permanent hearing loss in a large proportion of the patient population [39]. Current systemic approaches involving platinum binders and antioxidants appear to mitigate the ototoxicity but may reduce the effectiveness of the anti-cancer action of the cisplatin [40]. Therefore a local delivery approach that protects the cochlea without interfering with the therapeutic effect would be ideal. Similar effects are seen with radiation treatment of head and neck tumors, where approximately one-third of the patients suffer severe and irreversible hearing loss [41,42]. A related opportunity exists with antibiotic-associated ototoxicity seen with aminoglycoside compounds [43], where high frequency hearing loss is frequently experienced.

Two less common but very severe causes of hearing loss potentially addressable by intracochlear drug delivery include autoimmune inner ear disease (AIED) [44,45,46] and sudden sensorineural hearing loss (SSNHL) [47]. Typically AIED is treated with high-dose

systemic steroids, but side effects are so severe that many patients terminate therapy and move to a cochlear implant. While the efficacy of locally delivered steroids is unknown, AIED represents a potential early path to the clinic for intracochlear delivery systems where alternatives that preserve hearing structures do not exist and safety can be assessed using known, approved compounds. Like AIED, SSNHL represents another very promising avenue for intracochlear delivery, because current clinical practice involves the use of high-dose systemic steroids with dangerous side effects. Intratympanic delivery and a catheter-based approach have been used to treat this condition with some success [48,49].

c. Vestibular Diseases

Transtympanic injections of gentamicin represented the first local drug delivery application in the inner ear, aimed at treating Meniere's disease, a debilitating condition involving sudden, severe attacks of vertigo often associated with hearing loss and other symptoms. Microcatheters, microwicks and hydrogels for RWM application have all been developed with the goal of treating Meniere's disease by providing a more uniform and well-controlled rate of delivery. Safety concerns regarding the transtympanic administration of gentamicin, due to hearing loss incurred in many cases, have led to a reduction in the dosage that has improved safety while preserving efficacy [50,51]. Intralabyrinthine delivery represents an opportunity to deliver the drug directly to the site of disease, bypassing potential barriers to drug transport such as the middle ear and the RWM. Further, the possibility of enabling burst delivery in response to an impending attack of vertigo would provide additional benefit to patients, potentially through an implanted intracochlear delivery system.

d. Tinnitus

Tinnitus affects approximately 10% of the United States population, and has been the focus of intensive efforts in delivery technologies due to the potentially debilitating nature of the disease. Retraining, biofeedback and masking approaches have met with limited success [52], but pharmacologic approaches, typically via transtympanic injections, have been underway for over four decades. Dexamethasone and steroid delivery have also been demonstrated with moderate success in mitigating tinnitus while preserving hearing. However, each approach suffers from potential issues in assessing efficacy and safety as a function of dosage and duration of treatment. A direct intracochlear approach, particularly with programmable and adjustable rates of delivery, has the potential of addressing some of these concerns and resulting in a safer and more efficacious avenue for therapy.

3. Passive Intracochlear Delivery Systems

Intracochlear delivery systems may be broadly classified as either passive or active, depending upon whether there is a requirement for power and electronic controls embedded within the device. The following discussion summarizes several of the intracochlear delivery methods that have been explored, primarily in research laboratories in animal models, but some of which have been tested clinically. Table III provides a list of several of the intracochlear delivery methods investigated by researchers, along with relevant advantages and disadvantages for each approach.

a. Transtympanic Routes

Direct intracochlear delivery, the subject of this review, entails the surgical placement of a delivery device in direct communication with cochlear structures and the cochlear fluid. Prior delivery approaches through an intratympanic route will be briefly reviewed to provide a context for the development of direct intracochlear systems. The standard indirect approach for cochlear drug delivery is based upon introduction of compounds to the middle ear, followed by absorption into the inner ear. Needle injection into the middle ear is the

simplest approach, but a more involved procedure introduces drug through a myringotomy, sometimes through a tympanostomy tube [53]. A myringotomy has also been used to deliver drugs directly to the round window membrane through a Silverstein MicroWick® [11]; this technique has been used to treat SSNHL as well as Meniere's disease. Plontke [54] has reported the use of an implantable microcatheter placed in the round window niche; this system has been tested on 25 patients for treatment of SSNHL. Recent progress in treatment of Meniere's disease has been reported using IT injections of a steroid (OTO-104) that has been shown to reduce the severity of symptoms in a Phase 1b trial without adverse events [55].

In order to improve dosage control during intratympanic delivery, several groups have explored the use of nanoparticles and hydrogels as delivery vehicles. A major advantage of these systems is the ability to provide sustained delivery for extended periods of time using controlled release matrices, thereby greatly increasing the period of performance over prior liquid delivery sources. Nanoparticles offer the potential for more sustained and well-controlled delivery, and various compositions including biodegradable and non-degradable nanoparticle delivery systems have been explored for intracochlear therapy. A bioresorbable nanoparticle composition based on poly(lactic co-glycolic) acid (PLGA) has been reported by Tamura et al. [56]. This investigation confirmed the beneficial effects of nanoparticles on pharmacokinetics by demonstrating a significant increase in the concentration of a fluorescent label attached to the nanoparticles in the cochlea relative to levels seen when the fluorescent label was introduced either systemically or by application as a free molecule to the RWM. Superparamagnetic nanoparticles represent another delivery modality; magnetic fields have been used to guide these particles down the chinchilla cochlea [57] as a means to enhance apical delivery, although evidence for increased penetration depth is not clear. Liposomal delivery has been used for gene therapy [58]; the liposomes can either be injected or delivered using an osmotic pump.

Hydrogels exhibit great versatility as drug delivery vehicles for a range of clinical applications [59]. Triggering mechanisms for release of the hydrogel's drug payload include temperature, pH, pressure, electrical stimulation and chemical means. Brain-derived growth factor (BDNF) has been delivered using a hydrogel matrix applied to the RWM [60], with protective effects seen in SGN cells. Siloxane-based hydrogel systems [61] have been reported, but much emphasis has been placed on biodegradable hydrogels including PLGA [62]. Recent clinical trials have shown that topical application of insulin-like growth factor (IGF-1) results in measurable hearing improvement in about half the patients, with no adverse events [63].

b. Osmotic Pumps

Osmotic pumps provide a means to deliver drugs directly to tissues without the requirement for external connections or a power source. They operate by means of establishment of an osmotic gradient that drives drug out of a canister, and in the case of intracochlear delivery through a cannula into the inner ear, at a rate determined by the design of the device. Large molecules, proteins and peptides may be delivered by osmotic pumps, and therefore these devices have been used for a variety of intracochlear applications. An early demonstration of intracochlear drug delivery was reported by Kingma et al. [64]; guinea pigs received surgical placement of a micro-injector near the basal turn of the scala tympani. Animals received injections of either tetrodotoxin or saline solution as a control, and auditory brainstem response was monitored over periods of up to 2 weeks. Prieskorn and Miller [10] reported chronic intracochlear delivery using osmotic pumps (Alza Corp.), as well as chronically implanted cannulae for repeat drug infusions. Lalwani has reported a lentiviral vector as a gene delivery agent [65]. Ototoxicity protection during cisplatin-based chemotherapy represents another avenue of investigation for osmotic pumps; sodium

thiosulfate infused through a glass cannula from an osmotic pump has been shown to protect hair cells from the damaging effects of cisplatin [66].

4. Active Intracochlear Delivery Systems

Progress in the development of active intracochlear drug delivery systems has been spurred by parallel advances in surgical approaches to the inner ear and the development of miniaturized pumping systems based on microfluidics technologies. Surgical approaches for intracochlear delivery generally comprise either a cochleostomy (typically to the scala tympani although both the scala media and scala vestibuli have been explored as routes for delivery) or directly through the RWM. One of the primary challenges in intracochlear delivery involves the establishment of a robust fluidic connection to the cochlea; difficulties have been encountered in realizing an initial seal that does not leak at the cochleostomy site as well as with rejection of the cannula due to a foreign body response.

a. Constant Infusion Systems

Constant infusion systems used for direct intracochlear drug delivery include direct injections and syringe pump delivery [67,68,69]. The former approach has been used for gene transfer, liposomal delivery and agents capable of reducing damage associated with cochlear implant placement. The latter approach has been utilized experimentally to establish kinetic models for drug transport in the scala tympani as a basis for the development of miniaturized reciprocating delivery systems, as described in the next section.

An interesting intracochlear delivery system utilizing a constant infusion pump has been reported by Borkholder *et al.* [14]. This system utilizes a cochleostomy as a port for drug delivery using a constant infusion pump in combination with a canalostomy in the posterior semicircular canal designed to reduce concentration gradients and enhance drug transport and apical delivery. Salicylate delivery from a syringe pump was monitored using DPOAE and modeled using a computational approach developed by Salt *et al.* [70] Figure 2 illustrates the concentration gradients generated by constant infusion with and without the presence of the posterior canalostomy. These results clearly demonstrated that the canalostomy reduced the basal-to-apical concentration gradient, presumably by modulating fluidic resistance along the delivery path relative to clearance and other mechanisms.

b. Reciprocating Microfluidic Devices

The small space and fluid volume within the cochlea presents a particular challenge for drug delivery systems requiring adequate mixing and distribution to regions distant from the site of initial delivery. Constant infusion approaches as described in the previous section are hindered by the low rate of clearance of cochlear fluid and hence the limited volume of drug that can be introduced into the cochlea in a given time window. These difficulties are exacerbated by the relatively long, narrow passages within the cochlear tubes, and the increasing difficulty of surgically approaching more apical regions of the progressively narrowing and remote regions comprising the lower frequency hearing response. The aforementioned work of the Borkholder group, in which a canalostomy in the posterior semicircular canal was created to reduce concentration gradients, highlights this challenge related to moving drug apically through a long, narrow space with a severely limited maximum sustained flow rate. As a means to overcome this limitation, a reciprocating drug delivery system has been developed that provides zero net volume delivery by infusing and withdrawing a constant volume of drug in a cyclic fashion [15,16,17,18,71]. This approach is designed to enhance drug mixing and apical transport while limiting the maximum flow rate and maintaining the total volume of cochlear fluid. Typically the infusion portion of the

cycle lasts for several seconds using a total drug volume of roughly 1 microliter, while the remainder of the cycle lasts for several minutes as a mixture of drug and endogenous perilymph is withdrawn back into the device. This process is repeated in a cyclic fashion using a programmable pump. Current development efforts are focused on integration of delivery components in a microfluidic chip of a size suitable for implantation [72]; a prototype of this device is shown in Figure 3.

Initial studies with reciprocating delivery systems have utilized commercially available micropumps or a syringe pump programmed to provide cyclic infusion and withdrawal steps. These investigations, conducted using DNQX, a glutamate receptor antagonist, along with monitoring of CAP as an assay for drug transport and concentration as a function of location in the ST, have been used to establish a basic kinetic model for intracochlear delivery based primarily on drug diffusion. The relationship between apical transport and delivery parameters has been explored, as shown in Figure 4, as has the influence of instantaneous flow rate on hair cell damage. More complex mechanisms such as drug binding to proteins in the perilymph and clearance mechanisms through cochlear structures and tissues are being incorporated into next-generation kinetic models [18].

c. Cochlear Prosthesis-Mediated Delivery

One of the most logical routes to intracochlear drug delivery is to integrate the delivery system with the placement of a cochlear prosthesis [19,20,21,73,74], a device that provides a sense of sound to patients with significant or profound hearing loss by directly stimulating the auditory nerve. These devices, which comprise a microphone, transmitter, speech processor and electrode array, contain elements that are implanted directly into the inner ear, either via a cochleostomy or through the RWM [75]. Since the device is implanted directly into the cochlea, it provides a convenient pathway to deliver drugs to the inner ears of patients for a variety of potential applications. Delivery approaches include the use of drug-eluting polymers coated onto the implant device and the integration of active infusion pumps with the device.

One of the most direct applications of intracochlear delivery with a cochlear implant is the use of neurotrophic factors capable of preserving spiral ganglion (SG) cells and thereby enhancing hearing in implanted patients [76]. Neurotrophic factors such as BDNF and fibroblast growth factor-1 have been investigated as a means to preserve SG cells; in the former case survival and neurite outgrowth of SG cells in culture have been observed [77], while a combination of the two factors has been explored as a means to preserve SG cells in a guinea pig model [78]. In addition, Neurotrophin-3 has been incorporated in an electrically conducting polymer coating on cochlear implant electrodes in a guinea pig model [79].

Active drug delivery in the context of a cochlear implant is being explored through the use of catheters and infusion pumps integrated with the implant device. One of the driving forces for this approach is the desire to limit the structural damage caused by the cochlear implant, thereby enabling the device to be used for patients with less severe hearing loss than those typically receiving a conventional implant. This approach utilizes either a shortened electrode or partial insertion of a conventional electrode, limiting the region of damage to hearing structures to the highest frequencies. Delivery of specific compounds such as steroids has been shown to minimize the effects of surgical trauma, and offers a potential route to providing cochlear implants to a far wider patient population than current practice allows. Implants have been combined with infusion pumps to deliver drug through a catheter; most recently the implementation of a single-use catheter has been explored with a bolus injection from a syringe [80]. Laser machining of a cannula to provide numerous delivery ports is another method that has been explored as a means to improve apical distribution of drug in concert with a cochlear implant [81]. Approaches towards cochlear

implant-mediated delivery through an integrated cannula are illustrated in Figure 5 [82]. Finally, coating of cochlear implants using biodegradable materials such as polyvinyl alcohol has been shown to reduce insertion forces [83] and could potentially be used for drug delivery.

5. Conclusions

Intracochlear drug delivery systems represent a promising approach to treat a host of currently intractable diseases of the inner ear, ranging from auditory disorders such as severe hearing loss to vestibular conditions and tinnitus. Current approaches are severely limited by safety issues such as systemic effects and adverse reactions and by the inaccessibility of inner ear targets to oral, intravenous and even intratympanic administration. The first generation of intracochlear delivery devices, comprised primarily by miniaturized osmotic pumps and constant infusion micropumps, has demonstrated the ability to reach targets such as inner ear hair cells, but the short operational life of these devices and the lack of programmable control have limited their usefulness. More recent generations of intracochlear delivery systems incorporate precision micropumps with miniaturized power and electronic controls. These systems will ultimately serve as fully implantable therapeutic devices for extended delivery of pharmacologic compounds for treatment of inner ear diseases. In the nearer term, they will find utility as wearable and implantable systems for animal models, accelerating the pace of drug development and enabling a deeper understanding of the mechanisms underlying inner ear diseases and regeneration.

6. Expert Opinion

Intracochlear drug delivery systems are emerging in response to recent advances in molecular biology and understanding of the mechanisms underlying inner ear diseases, and as a means to overcome many of the barriers and limitations of conventional drug delivery approaches such as intratympanic administration. Inner ear diseases comprise an enormous and growing class of disorders affecting hundreds of millions of patients worldwide, and the aging population and increasing levels of exposure to noise are exacerbating the situation. Without a means to deliver drugs safely and efficaciously directly to the cochlea, the benefits of advances in discovery of regenerative compounds will not be realized, because of difficulties in reaching and targeting these sensitive and remote locations.

Current approaches rely on systemic delivery of steroids, antibiotics and other compounds, as well as intratympanic approaches where drugs are injected into the middle ear as liquids, gels or nanoparticles. Systemic delivery provides poor control over dosage and often leads to severe side effects and eventual cessation of therapy. Intratympanic delivery is typically much safer, but relies on transport across the round window membrane or other structures separating the middle ear from the cochlea. The pharmacokinetics of delivery across these structures is complex and very difficult to control, and therefore empirical approaches are typically employed. These limitations of systemic and intratympanic delivery, already significant with relatively simple drugs such as steroids, will be further exacerbated as more complex therapeutic approaches involving regeneration emerge. These systems will likely require timed-sequence delivery of multiple agents in a synchronized manner, necessitating the development of programmable devices with advanced functionality, capable of extended delivery in a partially or fully implantable format. Continued advances in pharmacokinetic models for intracochlear drug delivery [33,70,84,85,86,87,88] will be required in order to design safe and efficacious systems for a range of target diseases.

Initial development of intracochlear delivery systems has centered on the use of osmotic pumps, constant infusion pumps, and reciprocating delivery devices to enhance mixing and

apical transport. These efforts have been focused on miniaturization of pumps, sensors and control systems to enable wearable and ultimately implantable devices. The emergence of micropumps with low power requirements, high precision and a size suitable for implantation is providing an opportunity for next-generation drug delivery systems [89,90,91,92]. Advances towards the development of in vivo biosensors [93,94] for real-time monitoring of disease biomarkers and the bioactivity of delivered compounds represent another important element of future closed-loop delivery systems. In addition to the development of devices for human clinical use, researchers will also benefit from the availability of wearable systems for animal studies of disease mechanisms and for drug discovery. For the latter set of applications, untethered systems small enough to be worn by rodents, and with a drug payload sufficient for extended delivery, will be required. Several critical priorities must be addressed in order to bring these technologies into human clinical use. Foremost among these is safety; the device must be proven safe, preferably using compounds that are currently approved for therapeutic use, causing no harm to residual hearing or to other structures in the ear. In addition to hearing loss, other safety concerns with implants in the cochlea include risk of infection, a requirement for repeated surgical procedures, and the potential for limitations regarding magnetic resonance imaging. Drug storage and control over release must be implemented in a manner that allows acceptable control over dosage, preferably with the flexibility to alter delivery profiles in a patient-specific manner. Advances in controlled release systems and nanoparticle technology currently being explored using intratympanic delivery modes may be integrated with intracochlear delivery devices, thereby leading to a significant expansion in the versatility of these systems. Miniaturization of electronics and power sources represents another critical challenge that must be met in order to realize fully implantable intracochlear delivery systems, as the volume available for these devices is very limited [72]. Sensing capabilities, while perhaps not essential for first-generation systems, will ultimately add a degree of safety and better physician monitoring and control over delivery parameters. Regulatory hurdles for the coming generation of intracochlear delivery devices may be anticipated based on the precedents set by cochlear prostheses, which are implanted using a similar surgical procedure and represent a comparable level of technological complexity and integration of functionality. Along these lines, the most straightforward route to clinical use of these intracochlear delivery systems may be in concert with existing intracochlear devices such as cochlear implants. A drug delivery module associated with a cochlear implant, particularly one designed to preserve residual hearing structures, may provide patients with prosthetic hearing while simultaneously regenerating hair cells and neural cells to achieve superior levels of hearing and potential restoration of natural hearing function.

Acknowledgments

This publication was made possible by support from the NIH NIDCD, Grant Number 2 R01 DC006848-04A1 and its contents are solely the responsibility of the author and do not necessarily represent the official views of the NIH or the U.S. government.

List of Abbreviations

ABR	Auditory Brainstem Response
BDNF	Brain Derived Neurotrophic Factor
CAP	Compound Action Potential
CSF	Cerebrospinal Fluid
DNQX	(6,7-dinitroquinoxaline-2,3-dione)

DPOAE	Distortion Product Otoacoustic Emission HC Hair Cells
IHC	Inner Hair Cells
NIHL	Noise Induced Hearing Loss
OC	Organ of Corti
OHC	Outer Hair Cells
RNA	Ribonucleic Acid
RWM	Round Window Membrane
SG	Spiral Ganglion
SNHL	Sensorineural Hearing Loss
SSNHL	Sudden Sensorineural Hearing Loss
ST	Scala Tympani

References

- 1•. Holley MC. Keynote review: The auditory system, hearing loss and potential targets for drug development. *Drug Discov Today*. 2005; 10(19):1269–82. This paper is of considerable interest as it covers a broad spectrum of therapeutic opportunities for drug delivery systems to the inner ear. [PubMed: 16214671]
2. <http://www.vba.va.gov/REPORTS/abr/index.asp>
3. DePalma RG, Burris DG, Champion HR, et al. Blast injuries. *N Engl J Med*. 2005; 352(13):1335–42. [PubMed: 15800229]
4. Swan EE, Mescher MJ, Sewell WF, et al. Inner ear drug delivery for auditory applications. *Adv Drug Deliv Rev*. 2008; 60(15):1583–99. [PubMed: 18848590]
5. McCall AA, Swan EE, Borenstein JT, et al. Drug delivery for treatment of inner ear disease: current state of knowledge. *Ear Hear*. 31(2):156–65. [PubMed: 19952751]
6. Borkholder DA. State-of-the-art mechanisms of intracochlear drug delivery. *Curr Opin Otolaryngol Head Neck Surg*. 2008; 16(5):472–7. [PubMed: 18797291]
7. Theeuwes F, Yum SI. Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. *Ann Biomed Eng*. 1976; 4(4):343–53. [PubMed: 1020825]
8. Theeuwes F, Yum SI, Haak R, et al. Systems for triggered, pulsed, and programmed drug delivery. *Ann N Y Acad Sci*. 1991; 618:428–40. [PubMed: 2006800]
9. Brown JN, Miller JM, Altschuler RA, et al. Osmotic pump implant for chronic infusion of drugs into the inner ear. *Hear Res*. 1993; 70(2):167–72. [PubMed: 8294261]
10. Prieskorn DM, Miller JM. Technical report: chronic and acute intracochlear infusion in rodents. *Hear Res*. 2000; 140(1–2):212–5. [PubMed: 10675648]
11. Silverstein H. Use of a new device, the MicroWick, to deliver medication to the inner ear. *Ear Nose Throat J*. 1999; 78(8):595–8. 600. [PubMed: 10485154]
12. Silverstein H, Thompson J, Rosenberg SI, et al. Silverstein MicroWick. *Otolaryngol Clin North Am*. 2004; 37(5):1019–34. [PubMed: 15474108]
13. Hill SL 3rd, Digges EN, Silverstein H, et al. Long-term follow-up after gentamicin application via the Silverstein MicroWick in the treatment of Meniere's disease. *Ear Nose Throat J*. 2006; 85(8):494, 496, 498. [PubMed: 16999055]
- 14•. Borkholder DA, Zhu X, Hyatt BT, et al. Murine intracochlear drug delivery: reducing concentration gradients within the cochlea. *Hear Res*. 268:1–2. 2–11. This paper is of interest regarding the use of fluid mechanical approaches and simulations to control and optimize drug transport in the cochlea.

15. Chen Z, Kujawa SG, McKenna MJ, et al. Inner ear drug delivery via a reciprocating perfusion system in the guinea pig. *J Control Release*. 2005; 110(1):1–19. [PubMed: 16274830]
16. Fiering J, Mescher MJ, Swan EEL, et al. Local drug delivery with a self-contained, programmable, microfluidic system. *Biomed Microdevices*. 2009; 11(3):571–8. [PubMed: 19089621]
- 17•. Sewell, WF.; Borenstein, JT.; Chen, Z., et al. *Audiol Neurotol*. Vol. 14. 2009. Development of a microfluidics-based intracochlear drug delivery device; p. 411–22. This paper is of interest based on the investigation of the parameter space for delivery to understand and optimize the safety and efficacy of future therapeutic applications
18. Pararas EEL, Chen Z, Fiering J, et al. Kinetics of reciprocating drug delivery to the inner ear. *J Controlled Release*. 10.1016/j.jconrel.2011.02.021
19. Garnham C, Reetz G, Jolly C, et al. Drug delivery to the cochlea after implantation: consideration of the risk factors. *Cochlear Implants Int*. 2005; 6(Suppl 1):12–4. [PubMed: 18792345]
20. Hochmair I, Nopp P, Jolly C, et al. MED-EL Cochlear implants: state of the art and a glimpse into the future. *Trends Amplif*. 2006; 10(4):201–19. [PubMed: 17172548]
- 21•. Shepherd RK, Xu J. A multichannel scala tympani electrode array incorporating a drug delivery system for chronic intracochlear infusion. *Hear Res*. 2002; 172(1–2):92–8. This paper is of considerable interest because it offers a potentially near-term avenue for clinical application of intracochlear drug delivery systems in combination with a clinically approved device. [PubMed: 12361871]
22. Schuknecht, H. *Pathology of the ear*. Lea and Febiger; Malvern, PA: 1993.
23. Staecker H. Broadening the spectrum of treatment options for SNHL. *Arch Otolaryngol Head Neck Surg*. 2005; 131(8):734. [PubMed: 16103310]
24. Medina JE, Drescher DG. The amino-acid content of perilymph and cerebrospinal fluid from guinea-pigs and the effect of noise on the amino-acid composition of perilymph. *Neuroscience*. 1981; 6(3):505–9. [PubMed: 7219728]
25. Scheibe F, Haupt H. Biochemical differences between perilymph, cerebrospinal fluid and blood plasma in the guinea pig. *Hear Res*. 1985; 17(1):61–6. [PubMed: 3997682]
26. Swan EE, Peppi M, Chen Z, et al. Proteomics analysis of perilymph and cerebrospinal fluid in mouse. *Laryngoscope*. 2009; 119(5):953–8. [PubMed: 19358201]
27. Banfai P, Hortmann G, Kubik S, et al. Projection of the spiral cochlear canal on the medial wall of the tympanic cavity with regard to the cochlear implant. *Scand Audiol Suppl*. 1979; 11:157–70. [PubMed: 299183]
28. Adunka OF, Radeloff A, Gstottner WK, et al. Scala tympani cochleostomy II: topography and histology. *Laryngoscope*. 2007; 117(12):2195–200. [PubMed: 17909447]
29. Conn, MP. *Sourcebook of Models for Biomedical Research*. Vol. Chapter 32. Springer; New York: 2007.
30. Telischi FF, Widick MP, Lonsbury-Martin BL, et al. Monitoring cochlear function intraoperatively using distortion product otoacoustic emissions. *Am J Otol*. 1995; 16(5):597–608. [PubMed: 8588664]
31. Telischi FF, Stagner B, Widick MP, et al. Distortion-product otoacoustic emission monitoring of cochlear blood flow. *Laryngoscope*. 1998; 108(6):837–42. [PubMed: 9628498]
32. Gouveris H, Mann W. Association between surgical steps and intraoperative auditory brainstem response and electrocochleography waveforms during hearing preservation vestibular schwannoma surgery. *Eur Arch Otorhinolaryngol*. 2009; 266(2):225–9. [PubMed: 18553092]
- 33•. Salt AN, Plontke SK. Principles of local drug delivery to the inner ear. *Audiol Neurotol*. 2009; 14(6):350–60. This paper is of considerable interest because it covers a wide range of concepts and challenges associated with drug delivery to the inner ear, including pharmacokinetic principles and computational approaches. [PubMed: 19923805]
34. Littman T, Bobbin RP, Fallon M, et al. The quinoxalinediones DNOX, CNOX and two related congeners suppress hair cell-to-auditory nerve transmission. *Hear Res*. 1989; 40(1–2):45–53. [PubMed: 2570055]
35. Sendowski I, Abamrane L, Raffin F, et al. Therapeutic efficacy of intra-cochlear administration of methylprednisolone after acoustic trauma caused by gunshot noise in guinea pigs. *Hear Res*. 2006; 221(1–2):119–27. [PubMed: 17008037]

36. Lynch ED, Kil J. Compounds for the prevention and treatment of noise-induced hearing loss. *Drug Discov Today*. 2005; 10(19):1291–8. [PubMed: 16214673]
37. Chiu LL, Cunningham LL, Raible DW, et al. Using the zebrafish lateral line to screen for ototoxicity. *J Assoc Res Otolaryngol*. 2008; 9(2):178–90. [PubMed: 18408970]
38. Rybak LP, Kelly T. Ototoxicity: bioprotective mechanisms. *Curr Opin Otolaryngol Head Neck Surg*. 2003; 11(5):328–33. [PubMed: 14502062]
39. Rybak LP. Cis-platinum associated hearing loss. *J Laryngol Otol*. 1981; 95(7):745–7. [PubMed: 7195923]
40. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. *Drug Discov Today*. 2005; 10(19):1313–21. [PubMed: 16214676]
41. Bhandare N, Antonelli PJ, Morris CG, et al. Ototoxicity after radiotherapy for head and neck tumors. *Int J Radiat Oncol Biol Phys*. 2007; 67(2):469–79. [PubMed: 17236969]
42. Jereczek-Fossa BA, Zarowski A, Milani F, et al. Radiotherapy-induced ear toxicity. *Cancer Treat Rev*. 2003; 29(5):417–30. [PubMed: 12972360]
43. Himeno C, Komeda M, Izumikawa M, et al. Intra-cochlear administration of dexamethasone attenuates aminoglycoside ototoxicity in the guinea pig. *Hear Res*. 2002; 167(1–2):61–70. [PubMed: 12117531]
44. Ryan AF, Harris JP, Keithley EM, et al. Immune-mediated hearing loss: basic mechanisms and options for therapy. *Acta Otolaryngol Suppl*. 2002; (548):38–43. [PubMed: 12211356]
45. Yang GS, Song HT, Keithley EM, et al. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. *Am J Otol*. 2000; 21(4):499–504. [PubMed: 10912694]
46. Matteson EL, Fabry DA, Strome SE, et al. Autoimmune inner ear disease: diagnostic and therapeutic approaches in a multidisciplinary setting. *J Am Acad Audiol*. 2003; 14(4):225–30. [PubMed: 12940706]
47. Mosnier I, Bouccara D, Atassi-Dumont M, et al. Treatments of idiopathic sudden sensorineural hearing loss: retrospective study of 144 cases]. *Rev Laryngol Otol Rhinol (Bord)*. 1998; 119(2):119–28. [PubMed: 9770055]
48. Kopke RD, Hoffer ME, Wester D, et al. Targeted topical steroid therapy in sudden sensorineural hearing loss. *Otol Neurotol*. 2001; 22(4):475–9. [PubMed: 11449103]
49. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. *Otol Neurotol*. 2001; 22(1):18–23. [PubMed: 11314710]
50. Harner SG, Driscoll CL, Facer GW, et al. Long-term follow-up of transtympanic gentamicin for Meniere's syndrome. *Otol Neurotol*. 2001; 22(2):210–4. [PubMed: 11300271]
51. Chia SH, Gamst AC, Anderson JP, et al. Intratympanic gentamicin therapy for Meniere's disease: a meta-analysis. *Otol Neurotol*. 2004; 25(4):544–52. [PubMed: 15241234]
52. Hoffer ME, Wester D, Kopke RD, et al. Transtympanic management of tinnitus. *Otolaryngol Clin North Am*. 2003; 36(2):353–8. [PubMed: 12856303]
53. Licameli G, Johnston P, Luz J, et al. Phosphorylcholine-coated antibiotic tympanostomy tubes: are post-tube placement complications reduced? *Int J Pediatr Otorhinolaryngol*. 2008; 72(9):1323–8. [PubMed: 18635268]
54. Plontke S, Lowenheim H, Preyer S, et al. Outcomes research analysis of continuous intratympanic glucocorticoid delivery in patients with acute severe to profound hearing loss: basis for planning randomized controlled trials. *Acta Otolaryngol*. 2005; 125(8):830–9. [PubMed: 16158529]
55. <http://clinicaltrials.gov/ct2/show/NCT01084525>
56. Tamura T, Kita T, Nakagawa T, et al. Drug delivery to the cochlea using PLGA nanoparticles. *Laryngoscope*. 2005; 115(11):2000–5. [PubMed: 16319613]
57. Ge X, Jackson RL, Liu J, et al. Distribution of PLGA nanoparticles in chinchilla cochleae. *Otolaryngol Head Neck Surg*. 2007; 137(4):619–23. [PubMed: 17903580]
58. Wareing M, Mhatre AN, Pettis R, et al. Cationic liposome mediated transgene expression in the guinea pig cochlea. *Hear Res*. 1999; 128(1–2):61–9. [PubMed: 10082284]
59. Saltzman, WM. *Engineering Principles for Drug Delivery*. Oxford; New York: 2001.

60. Endo T, Nakagawa T, Kita T, et al. Novel strategy for treatment of inner ears using a biodegradable gel. *Laryngoscope*. 2005; 115(11):2016–20. [PubMed: 16319616]
61. Arnold W, Senn P, Hennig M, et al. Novel slow-and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs. *Audiol Neurotol*. 2005; 10(1):53–63. [PubMed: 15591792]
62. Ito J, Endo T, Nakagawa T, et al. A new method for drug application to the inner ear. *ORL J Otorhinolaryngol Relat Spec*. 2005; 67(5):272–5. [PubMed: 16374059]
63. Nakagawa T, Sakamoto T, Hiraumi H, et al. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. *BMC Med*. 2010; 8:76. [PubMed: 21108784]
64. Kingma GG, Miller JM, Myers MW, et al. Chronic drug infusion into the scala tympani of the guinea pig cochlea. *J Neurosci Methods*. 1992; 45(1–2):127–34. [PubMed: 1491594]
65. Carvalho GJ, Lalwani AK. The effect of cochleostomy and intracochlear infusion on auditory brain stem response threshold in the guinea pig. *Am J Otol*. 1999; 20(1):87–90. [PubMed: 9918180]
66. Wang J, Lloyd Faulconbridge RV, Fetoni A, et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. *Neuropharmacology*. 2003; 45(3):380–93. [PubMed: 12871655]
67. Praetorius M, Baker K, Brough DE, et al. Pharmacodynamics of adenovector distribution within the inner ear tissues of the mouse. *Hear Res*. 2007; 227(1–2):53–8. [PubMed: 17081711]
68. Oestreicher E, Arnold W, Ehrenberger K, et al. New approaches for inner ear therapy with glutamate antagonists. *Acta Otolaryngol*. 1999; 119(2):174–8. [PubMed: 10320071]
69. Stover T, Yagi M, Raphael Y, et al. Cochlear gene transfer: round window versus cochleostomy inoculation. *Hear Res*. 1999; 136(1–2):124–30. [PubMed: 10511631]
70. Plontke SK, Siedow N, Wegener R, et al. Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. *Audiol Neurotol*. 2007; 12(1):37–48. [PubMed: 17119332]
71. Mescher MJ, Swan EE, Fiering J, et al. Fabrication Methods and Performance of Low-Permeability Microfluidic Components for a Miniaturized Wearable Drug Delivery System. *J Microelectromech Syst*. 2009; 18(3):501–510. [PubMed: 20852729]
72. Handzel O, Wang H, Fiering J, et al. Mastoid cavity dimensions and shape: method of measurement and virtual fitting of implantable devices. *Audiol Neurotol*. 2009; 14(5):308–14. [PubMed: 19372649]
73. Pettingill LN, Richardson RT, Wise AK, et al. Neurotrophic factors and neural prostheses: potential clinical applications based upon findings in the auditory system. *IEEE Trans Biomed Eng*. 2007; 54(6 Pt 1):1138–48. [PubMed: 17551571]
74. Paasche G, Gibson P, Averbek T, et al. Technical report: modification of a cochlear implant electrode for drug delivery to the inner ear. *Otol Neurotol*. 2003; 24(2):222–7. [PubMed: 12621336]
75. Briggs RJ, Tykocinski M, Xu J, et al. Comparison of round window and cochleostomy approaches with a prototype hearing preservation electrode. *Audiol Neurotol*. 2006; 11(Suppl 1):42–8. [PubMed: 17063010]
76. Incesulu A, Nadol JB Jr. Correlation of acoustic threshold measures and spiral ganglion cell survival in severe to profound sensorineural hearing loss: implications for cochlear implantation. *Ann Otol Rhinol Laryngol*. 1998; 107(11 Pt 1):906–11. [PubMed: 9823838]
77. Warnecke A, Wissel K, Hoffman A, et al. The biological effects of cell-delivered brain-derived neurotrophic factor on cultured spiral ganglion cells. *Neuroreport*. 2007; 18(16):1683–6. [PubMed: 17921868]
78. Miller JM, Le Prell CG, Prieskorn DM, et al. Delayed neurotrophin treatment following deafness rescues spiral ganglion cells from death and promotes regrowth of auditory nerve peripheral processes: effects of brain-derived neurotrophic factor and fibroblast growth factor. *J Neurosci Res*. 2007; 85(9):1959–69. [PubMed: 17492794]
79. Richardson RT, Wise AK, Thompson BC, et al. Polypyrrole-coated electrodes for the delivery of charge and neurotrophins to cochlear neurons. *Biomaterials*. 2009; 30(13):2614–24. [PubMed: 19178943]

80. Ibrahim HN, Bossard D, Jolly C, et al. Radiologic study of a disposable drug delivery intracochlear catheter. *Otol Neurotol*. 32(2):217–22. [PubMed: 21178805]
81. Paasche G, Bogel L, Leinung M, et al. Substance distribution in a cochlea model using different pump rates for cochlear implant drug delivery electrode prototypes. *Hear Res*. 2006; 212(1–2):74–82. [PubMed: 16337758]
82. Staecker H, Jolly C, Garnham C, et al. Cochlear implantation: an opportunity for drug development. *Drug Discov Today*. 15(7–8):314–21. [PubMed: 20184966]
83. Radeloff A, Unkelbach MH, Mack MG, et al. Acoated electrode carrier for cochlear implantation reduces insertion forces. *Laryngoscope*. 2009; 119(5):959–63. [PubMed: 19358253]
84. Salt AN. Pharmacokinetics of Drug Entry into Cochlear Fluids. *Volta Rev*. 2005; 105(3):277–298. [PubMed: 17330152]
85. Plontke SK, Salt AN. Simulation of application strategies for local drug delivery to the inner ear. *ORL J Otorhinolaryngol Relat Spec*. 2006; 68(6):386–92. [PubMed: 17065834]
86. Salt AN, Plontke SK. Local inner-ear drug delivery and pharmacokinetics. *Drug Discov Today*. 2005; 10(19):1299–306. [PubMed: 16214674]
87. Plontke SK, Salt AN. Quantitative interpretation of corticosteroid pharmacokinetics in inner fluids using computer simulations. *Hear Res*. 2003; 182(1–2):34–42. [PubMed: 12948599]
88. Salt AN. Simulation of methods for drug delivery to the cochlear fluids. *Adv Otorhinolaryngol*. 2002; 59:140–8. [PubMed: 11885655]
89. Maillefer, D.; Gamper, S.; Frehner, B., et al. IEEE MEMS 01. IEEE Press; 2001. A high-performance silicon micropump for disposable drug delivery systems.
90. Darby SG, Moore MR, Friedlander TA, et al. A metering rotary nanopump for microfluidic systems. *Lab Chip*. 10(23):3218–26. [PubMed: 20959938]
91. Abe C, Tashiro T, Tanaka K, et al. A novel type of implantable and programmable infusion pump for small laboratory animals. *J Pharmacol Toxicol Methods*. 2009; 59(1):7–12. [PubMed: 18852057]
92. Cao L, Mantell S, Polla D, et al. Design and simulation of an implantable medical drug delivery system using microelectromechanical systems technology. *Sensors and Actuators A*. 2001; 94:117–125.
93. Nguyen QT, Schroeder LF, Mank M, et al. An in vivo biosensor for neurotransmitter release and in situ receptor activity. *Nat Neurosci*. 13(1):127–32. [PubMed: 20010818]
94. Tierney S, Falch BM, Hjelme DR, et al. Determination of glucose levels using a functionalized hydrogel-optical fiber biosensor: toward continuous monitoring of blood glucose in vivo. *Anal Chem*. 2009; 81(9):3630–6. [PubMed: 19323502]

Article Highlights

- Local drug delivery systems represent a very high priority for next generation clinical approaches for treatment of diseases of the inner ear
- Diseases of the inner ear affect the lives of hundreds of millions of patients worldwide
- Passive delivery systems have been explored as a means to overcome barriers to delivery of compounds to the inner ear
- Active delivery systems capable of extended, programmable delivery are emerging in response to needs related to specific inner ear diseases
- Further miniaturization and integration of delivery and sensing functions will be required for the development of implantable intracochlear drug delivery systems

Fig 1.
Cast of a guinea pig cochlea, showing the locations along the length of the scala tympani where various frequencies are detected, along with a notional placement of a cannula for intracochlear drug delivery near the 30 kHz point.

Fig 2.

Image showing a drug delivery technique in which drug is infused into the scala tympani near the base, and a posterior canalostomy is opened to reduce concentration gradients by modulating the resistance along the delivery path. Reprinted from Ref [14], Hearing Research, Vol. 268, D.A. Borkholder et al., "Murine intracochlear drug delivery: Reducing concentration gradients within the cochlea", pp. 2-11, (2010), with permission from Elsevier.

Fig 3. Photograph with dimensions of microfluidic intracochlear drug delivery chip developed by Draper Laboratory and the Massachusetts Eye and Ear Infirmary, containing a displacement chamber, valves and fluidic vias for delivery of compounds through a single cannula into the cochlea using a reciprocating delivery profile.

Fig 4.

Three flow profiles are shown, all of which were used to deliver DNQX (300 µM), a glutamate receptor blocker that elevates thresholds for the compound action potential (CAP). Flow profiles from the early prototype [15], shown in black, produced threshold alterations (**center**) of around 25 dB at high CFs that built up slowly during the delivery period (shaded bar). **Right** Modification of the delivery profile (blue) produced larger and more rapid changes in CAP thresholds (around 40 dB for high characteristic frequencies (CFs). Further modification (red) induced threshold changes unrelated to drug delivery (data not shown).

Fig 5.

Illustration of two methods of drug delivery from a cochlear implant device is given. (a) Prototype of a catheter designed for atraumatic insertion into the cochlea, shown inserted into a model of the cochlea and attached to a syringe. The catheter can be up to 20 mm in length and has thin walls and a small wall diameter, resulting in a highly flexible construction. (b) Insertion of an electrode array highlighted by green dye infused from the catheter. (c) Drug delivery enabled by laser-drilled holes of 50 micron diameter to enable enhanced drug distribution in the cochlea. (d) Elution of pharmaceutical-grade dexamethasone mixed with medical-grade silicone elastomer; the drug is contained in the lower region (opaque). Reprinted from Ref [], *Drug Discovery Today*, Vol. 15, H. Staecker et al., "Cochlear implantation: an opportunity for drug development", pp. 314-321, (2010), with permission from Elsevier.

Table I

Partial list of inner ear diseases potentially amenable to intracochlear drug delivery, along with salient comments regarding the patient population and broad requirements for each condition.

Inner Ear Disease	Considerations for Drug Delivery
Sensorineural Hearing Loss	Largest patient population May require extended delivery of multiple compounds for regeneration
Noise-Induced Hearing Loss	Large and rapidly growing patient population May require timed-sequenced delivery High priority for Department of Defense
Sudden Sensorineural Hearing Loss	Rapid intervention required Therapeutics suitable for local delivery may already exist
Autoimmune Inner Ear Disease	Small patient population but urgent need Therapeutics suitable for local delivery may already exist
Menieres Disease	Relatively large patient population May require patient-controlled burst delivery
Tinnitus	Very large patient population with complex spectrum
Cisplatin Ototoxicity Protection	Very important for pediatric population Therapeutics suitable for local delivery may already exist Duration of delivery weeks to months
Radiation-Induced Ototoxicity Protection	Occurs in large percentage of patients with range of head and neck tumors Duration of delivery weeks to months
Cranial Nerve Schwannoma	Potential alternative to surgery May require extended delivery

Table II

Sampling of therapeutic compounds in development towards a range of diseases of the inner ear, including disease target, state of development, and current status.

Company	Therapeutic	Developed for	Category	Description	Status
Quark Pharmaceuticals	AHLi	Acute Hearing Loss-Apoptosis Prevention	siRNA	Temporarily inhibits expression of p53 tumor repressor gene	Pre-clinical, IND Submission 2009
Sound Pharmaceuticals	SPL-128	Regeneration	siRNA	Temporarily inhibits expression of cyclin-dependent kinase inhibitor IB	Pre-clinical
Merck & Co.	-	Apoptosis Prevention	siRNA	Temporarily inhibits expression of Rb 1	Pre-clinical
Kinex Pharmaceuticals	KX1-004	MHL, Cisplatin Ototoxicity	Small Molecule	Src inhibitor	Pre-clinical
Adherex	STS	Cisplatin Ototoxicity	Antioxidant	Sodium Thiosulfate	Orphan
GenVec	TherAtoh	Regeneration	Gene	Human atonal gene Hath1 vector	Pre-clinical
Auris Medical	AM-111	MHL, Aminoglycoside Ototoxicity	Small Molecule	Block JNK MAPK mediated apoptosis from stress injury	Orphan, Phase IIb
Living Cell Technologies	NeurotrophinCell	Degeneration Prevention	Cell	Pig cells encapsulated in alginate beads (500 microns)	Pre-clinical
Otonomy	OTO-104	Meniere's Disease	Steroid	intratympanic Injection	Phase Ib clinical trial
Neurosystec	NST-001	Tinnitus	NMDA antagonist	Osmotic pump	Phase Ib clinical trial

Table III

List of intracochlear delivery approaches and their perceived advantages and disadvantages.

Delivery Method	Advantages	Disadvantages
Osmotic Pumps	Flexible Payload Small No Power Required	Cannot turn off or alter profile Limited delivery duration
Direct Injection	Simple Already demonstrated clinically	Single administration Poor control over distribution
Micro-Injector	Simple Already demonstrated clinically Range of infusion rates possible	Challenging surgically Issues with robustness Component-level approach Prone to fouling Poor distribution kinetics
Infusion with Canalostomy	Provides superior distribution kinetics	Multiple surgical sites
Reciprocating System	Wide range of operating conditions May reduce fouling Capable of timed-sequence delivery	Issues with robustness Complex mechanism
Cochlear Implant Mediated Delivery	Integrated with well-established therapy Enhances clinical benefit of implant	Limits therapy to more severely impaired patients May involve complications due to interactions between implant operation and delivery device